Category: Heparin

Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies

Posted on | Posted on John Murphy | Leave a Comment on Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies

Suo-wen Xu, Iqra Ilyas & Jian-ping Weng Acta Pharmacologica Sinica volume 44, pages695–709 (2023) Nature Abstract The fight against coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is still raging. However, the pathophysiology of acute and post-acute manifestations of COVID-19 (long COVID-19) is understudied. Endothelial cells are sentinels lining the innermost layer of blood vessel that gatekeep micro- and macro-vascular health by […]

Acute hepatitis with autoimmune features after COVID-19 vaccine: coincidence or vaccine-induced phenomenon?

Posted on | Posted on John Murphy | Leave a Comment on Acute hepatitis with autoimmune features after COVID-19 vaccine: coincidence or vaccine-induced phenomenon?

Authors: José M Pinazo-Bandera 1, Alicia Hernández-Albújar 1, Ana Isabel García-Salguero 2,  Isabel Arranz-Salas 2, Raúl J Andrade 1 3, Mercedes Robles-Díaz 1 3 Gastroenterol Rep (Oxf) 2022 Apr 27;10:goac014. doi: 10.1093/gastro/goac014. eCollection 2022. Introduction Autoimmune diseases result from a breach of immunological self-tolerance and tissue damage by autoreactive T lymphocytes. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is characterized by an inflammatory dysregulation that has been associated with […]

COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies

Posted on | Posted on John Murphy | Leave a Comment on COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies

Authors: Eleonora Calabretta, 1 , 12 Jose M. Moraleda, 2 Massimo Iacobelli, 3 Ruben Jara, 4 Israel Vlodavsky, 5 Peter O’Gorman, 6 Antonio Pagliuca, 7 Clifton Mo, 8 Rebecca M. Baron, 9 Alessio Aghemo, 10 , 12 Robert Soiffer, 8 Jawed Fareed, 11 Carmelo Carlo‐Stella, 1 , 12 , * and Paul Richardson 8 , * Br J Haematol. 2021 Apr; 193(1): 43–51.Published online 2021 Feb 4.  doi:  10.1111/bjh.17240 PMCID:  PMC8014053PMID: 33538335 Introduction The coronavirus disease 2019 (COVID‐19) pandemic, a viral illness caused by the severe acute respiratory syndrome coronavirus‐2 […]

Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19

Posted on | Posted on John Murphy | Leave a Comment on Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19

Authors: JACC State-of-the-Art ReviewAzita H. Talasaz, PharmD,a,bParham Sadeghipour, MD,cHessam Kakavand, PharmD,a,bMaryam Aghakouchakzadeh, PharmD,aElaheh Kordzadeh-Kermani, PharmD,aBenjamin W. Van Tassell, PharmD,d,eAzin Gheymati, PharmD,aHamid Ariannejad, MD,bSeyed Hossein Hosseini, PharmD,aSepehr Jamalkhani,cMichelle Sholzberg, MDCM, MSc,f,gManuel Monreal, MD, PhD,hDavid Jimenez, MD, PhD,iGregory Piazza, MD, MS,jSahil A. Parikh, MD,k,lAjay J. Kirtane, MD, SM,k,lJohn W. Eikelboom, MBBS,mJean M. Connors, MD,nBeverley J. Hunt, MD,oStavros V. […]

COVID-19 vaccines and thrombosis with thrombocytopenia syndrome

Posted on | Posted on John Murphy | Leave a Comment on COVID-19 vaccines and thrombosis with thrombocytopenia syndrome

Authors: Chih-Cheng Lai 1, Wen-Chien Ko 2, Chih-Jung Chen 3, Po-Yen Chen 4, Yhu-Chering Huang 3, Ping-Ing Lee 5, Po-Ren Hsueh 6 7 Abstract Introduction: To combat COVID-19, scientists all over the world have expedited the process of vaccine development. Although interim analyses of clinical trials have demonstrated the efficacy and safety of COVID-19 vaccines, a serious but rare adverse event, thrombosis with thrombocytopenia syndrome (TTS), has been reported following […]

Anticoagulation in COVID-19: current concepts and controversies

Posted on | Posted on John Murphy | Leave a Comment on Anticoagulation in COVID-19: current concepts and controversies

Authors: http://orcid.org/0000-0002-3809-8926Atanu Chandra1, 6289Uddalak Chakraborty2, Shrestha Ghosh1, Sugata Dasgupta3 Abstract Rising incidence of thromboembolism secondary to COVID-19 has become a global concern, with several surveys reporting increased mortality rates. Thrombogenic potential of the SARS-CoV-2 virus has been hypothesised to originate from its ability to produce an exaggerated inflammatory response leading to endothelial dysfunction. Anticoagulants have remained the primary […]